Evidence map›Paper›PMID 35503177›Full record

ReviewAdvances in experimental medicine and biology2022

Sphingolipid Metabolism and Signaling in Endothelial Cell Functions.

Linda Sasset, Annarita Di Lorenzo

Open access · greenAbstract readReview
In one paragraph

Review in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Screening Probiotics for Anti-Foods (Basel, Switzerland) · 2024
    Article
  19. Article
  20. Endotheliopathy: Additional Players Slow the Downward Spiral.Arteriosclerosis, thrombosis, and vascular biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Linda SassetDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Feil Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
Annarita Di LorenzoDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Feil Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. and2039@med.cornell.edu.
Cornell University · USMIND Research Institute · US

Funding

Endothelial Sphingolipid Synthesis and Tissue Inflammatory ResponseR01HL126913 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DI LORENZO, ANNARITA · 2015 to 2023
$3.5M
SPHINGOLIPID BIOLOGY OF MACROPHAGE IN CORONARY ATHEROSCLEROSIS DEVELOPMENT AND PROGRESSIONR01HL152195 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DI LORENZO, ANNARITA · 2021 to 2024
$2.4M
NHLBI NIH HHS R01 HL126913NHLBI NIH HHS R01 HL152195
6 · The paper itself

Abstract

The endothelium, inner layer of blood vessels, constitutes a metabolically active paracrine, endocrine, and autocrine organ, able to sense the neighboring environment and exert a variety of biological functions important to preserve the health of vasculature, tissues, and organs. Sphingolipids are both fundamental structural components of the eukaryotic membranes and signaling molecules regulating a variety of biological functions. Ceramide and sphingosine-1-phosphate (S1P), bioactive sphingolipids, have emerged as important regulators of cardiovascular functions in health and disease. In this review we discuss recent insights into the role of ceramide and S1P biosynthesis and signaling in regulating endothelial cell functions, in health and diseases. We also highlight advances into the mechanisms regulating serine palmitoyltransferase, the first and rate-limiting enzyme of de novo sphingolipid biosynthesis, with an emphasis on its inhibitors, ORMDL and NOGO-B. Understanding the molecular mechanisms regulating the sphingolipid de novo biosynthesis may provide the foundation for therapeutic modulation of this pathway in a variety of conditions, including cardiovascular diseases, associated with derangement of this pathway.

Indexed as

CeramidesSphingolipidsEndothelial CellsEndotheliumSignal TransductionCeramidesSphingolipidsCeramideEndothelial cellsNogo-BSerine palmitoyltransferase (SPT)Sphingolipid de novo biosynthesisSphingosine-1-phosphate (S1P)

Identifiers

PMID35503177
PMCPMC12938882
OpenAlexW4285185495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.